EU Clinical Trial 2018-003243-39

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis  May 21, 2019

Main objective of the trial: To assess the efficacy of ravulizumab compared with placebo in the treatment of gMG based on the improvement in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) profile. Evaluar la eficacia de ravulizumab en comparación con el placebo en el tratamiento de la MGg basándose en la mejora del perfil de miastenia gravis-actividades de la vida diaria (MG-AVD).

Parties

Sponsors
Countries
AT CA CH DE DK ES IL IT JP KR NL US
Keywords
ALXN1210 Fc- and CDR-modified humanised monoclonal antibody against C5 Myasthenia gravis and related conditions Ravulizumab

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.